Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine

Alexion Pharmaceuticals completes Syntimmune acquisition

I-MAB Biopharma Co and Genexine receive Chinese authority's approval for Investigational New Drug application of TJ107

OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104 from Janssen Biotech

Pharm-Olam Conducts Pivotal Orphan Disease Trial, Leads to First Therapeutic Approved for the Treatment for Acquired Thrombotic Thrombocytopenic Purpura

US FDA grants approval to Sandoz's Hyrimoz

Horizon Pharma Presents Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab 

AstraZeneca signs agreement to divest rights to Nexium in Europe and Vimovo worldwide (ex-US) to Grünenthal

Grünenthal to acquire European rights to Nexium and global (ex US and Japan) rights to Vimovo

Alpine Immune Sciences' Lead Programme ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological Inflammation

PredictImmune Granted New Patent Grants and Allowances Across the UK, EU and Canada

Biogen launches adalimumab biosimilar, referencing Humira(R), in the Europan Union

Hansa Medical's receives Fast Track Designation from US FDA for Imlifidase for transplantation

The Menarini Group signs commercial agreement for Vabomere, Orbactiv and Minocin to treat infections in 68 countries

Grifols passes US FDA approval for use of ID CORE XT test kit for molecular red blood cell typing